Compare WEAV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | ALT |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 421.5M |
| IPO Year | 2021 | 2005 |
| Metric | WEAV | ALT |
|---|---|---|
| Price | $5.20 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.00 | ★ $17.67 |
| AVG Volume (30 Days) | 861.8K | ★ 2.8M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | $41,000.00 |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.99 | ★ 105.00 |
| 52 Week Low | $4.24 | $2.56 |
| 52 Week High | $9.10 | $7.73 |
| Indicator | WEAV | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 42.50 |
| Support Level | $4.93 | $2.57 |
| Resistance Level | $5.56 | $4.19 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 9.82 | 27.34 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.